A single-center study suggests complement inhibitors do not reduce the severity of a COVID-19 Omicron infection in patients with paroxysmal nocturnal hemoglobinuria (PNH). A COVID-19 infection can ...
TSP-1 reduced C3 and C5 cleavage and formation of the membrane attack complex, attenuating complement-mediated injury in AAV models. Complement activation is a relevant driver in the pathomechanisms ...
A localized complement-dependent hemolytic assay in modified Cunningham chambers for enumerating avian immunoglobulin-M (IgM)-secreting spleen cells is defined. The maximum number of IgM-secreting ...
Left untreated, PNH could cause death in about half of patients within 10 years of diagnosis. The primary cause of PNH-related mortality is thromboembolic events. A host of anti-complement strategies, ...
Patients who are taking complement inhibitors may still experience breakthrough hemolysis associated with respiratory viral infections. Patients with PNH should be closely monitored for signs of ...
"Atypical Hemolytic Uremic Syndrome Pipeline"Following the success of terminal complement inhibitors like eculizumab and ravulizumab, the therapeutic focus in 2025 has shifted towards developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback